Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 2
1984 2
1985 1
1986 1
1987 1
1988 1
1989 1
1990 2
1991 8
1992 3
1993 1
1994 4
1995 3
1996 2
1997 3
1998 9
1999 7
2000 6
2001 4
2002 13
2003 14
2004 9
2005 3
2006 11
2007 13
2008 9
2009 8
2010 8
2011 9
2012 8
2013 7
2014 7
2015 3
2016 4
2017 6
2018 2
2019 1
2020 7
2021 6
2023 1
2024 1
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

199 results

Results by year

Filters applied: . Clear all
Page 1
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
[No authors listed] [No authors listed] Lancet. 1998 Sep 12;352(9131):854-65. Lancet. 1998. PMID: 9742977 Clinical Trial.
A secondary analysis compared the 342 patients allocated metformin with 951 overweight patients allocated intensive blood-glucose control with chlorpropamide (n=265), glibenclamide (n=277), or insulin (n=409). ...Among patients allocated intensive blood-glucose cont …
A secondary analysis compared the 342 patients allocated metformin with 951 overweight patients allocated intensive blood-glucose con …
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G; ADOPT Study Group. Kahn SE, et al. N Engl J Med. 2006 Dec 7;355(23):2427-43. doi: 10.1056/NEJMoa066224. Epub 2006 Dec 4. N Engl J Med. 2006. PMID: 17145742 Free article. Clinical Trial.
RESULTS: Kaplan-Meier analysis showed a cumulative incidence of monotherapy failure at 5 years of 15% with rosiglitazone, 21% with metformin, and 34% with glyburide. This represents a risk reduction of 32% for rosiglitazone, as compared with metformin, and 63 …
RESULTS: Kaplan-Meier analysis showed a cumulative incidence of monotherapy failure at 5 years of 15% with rosiglitazone, 21% with metfor …
Pharmacodynamics of Glyburide, Metformin, and Glyburide/Metformin Combination Therapy in the Treatment of Gestational Diabetes Mellitus.
Shuster DL, Shireman LM, Ma X, Shen DD, Flood Nichols SK, Ahmed MS, Clark S, Caritis S, Venkataramanan R, Haas DM, Quinney SK, Haneline LS, Tita AT, Manuck TA, Thummel KE, Brown LM, Ren Z, Brown Z, Easterling TR, Hebert MF. Shuster DL, et al. Clin Pharmacol Ther. 2020 Jun;107(6):1362-1372. doi: 10.1002/cpt.1749. Epub 2020 Jan 25. Clin Pharmacol Ther. 2020. PMID: 31869430 Free PMC article. Clinical Trial.
Data are limited regarding the pharmacodynamic effects of metformin and glyburide during pregnancy. This study characterized insulin sensitivity (SI), beta-cell responsivity, and disposition index (DI) in women with GDM utilizing a mixed-meal tolerance test (MMTT) b …
Data are limited regarding the pharmacodynamic effects of metformin and glyburide during pregnancy. This study characterized i …
Pharmacokinetics and bioavailability of a metformin/glyburide tablet administered alone and with food.
Marathe PH, Arnold ME, Meeker J, Greene DS, Barbhaiya RH. Marathe PH, et al. J Clin Pharmacol. 2000 Dec;40(12 Pt 2):1494-502. J Clin Pharmacol. 2000. PMID: 11185672 Clinical Trial.
Two randomized crossover studies were conducted to evaluate the pharmacokinetics (including food effect) of fixed-combination metformin/glyburide tablets. Pharmacokinetics and bioavailability of two strengths (500 mg/2.5 mg and 500 mg/5 mg) of metformin/gl …
Two randomized crossover studies were conducted to evaluate the pharmacokinetics (including food effect) of fixed-combination metformin …
Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants.
Devineni D, Manitpisitkul P, Murphy J, Skee D, Wajs E, Mamidi RN, Tian H, Vandebosch A, Wang SS, Verhaeghe T, Stieltjes H, Usiskin K. Devineni D, et al. Clin Pharmacol Drug Dev. 2015 May-Jun;4(3):226-36. doi: 10.1002/cpdd.166. Epub 2014 Oct 27. Clin Pharmacol Drug Dev. 2015. PMID: 27140803 Clinical Trial.
Drug-drug interactions between canagliflozin, a sodium glucose co-transporter 2 inhibitor, and glyburide, metformin, and simvastatin were evaluated in three phase-1 studies in healthy participants. ...No drug-drug interactions were observed between canagliflozin and …
Drug-drug interactions between canagliflozin, a sodium glucose co-transporter 2 inhibitor, and glyburide, metformin, and simva …
Effects of rosiglitazone, glyburide, and metformin on beta-cell function and insulin sensitivity in ADOPT.
Kahn SE, Lachin JM, Zinman B, Haffner SM, Aftring RP, Paul G, Kravitz BG, Herman WH, Viberti G, Holman RR; ADOPT Study Group. Kahn SE, et al. Diabetes. 2011 May;60(5):1552-60. doi: 10.2337/db10-1392. Epub 2011 Mar 17. Diabetes. 2011. PMID: 21415383 Free PMC article. Clinical Trial.
RESEARCH DESIGN AND METHODS: Recently diagnosed, drug-naive patients with type 2 diabetes (4,360 total) were treated for a median of 4.0 years with rosiglitazone, metformin, or glyburide and were examined with periodic metabolic testing using an OGTT. ...CONCLUSIONS …
RESEARCH DESIGN AND METHODS: Recently diagnosed, drug-naive patients with type 2 diabetes (4,360 total) were treated for a median of 4.0 yea …
Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes.
Zinman B, Haffner SM, Herman WH, Holman RR, Lachin JM, Kravitz BG, Paul G, Jones NP, Aftring RP, Viberti G, Kahn SE; ADOPT Study Group. Zinman B, et al. J Clin Endocrinol Metab. 2010 Jan;95(1):134-42. doi: 10.1210/jc.2009-0572. Epub 2009 Oct 29. J Clin Endocrinol Metab. 2010. PMID: 19875477 Clinical Trial.
RESEARCH DESIGN AND METHODS: Paired stored baseline and 12-month serum samples were available from 1605 participants (689 women, 916 men) in ADOPT, a long-term clinical trial comparing the effects of rosiglitazone, glyburide, and metformin on glycemic control in pat …
RESEARCH DESIGN AND METHODS: Paired stored baseline and 12-month serum samples were available from 1605 participants (689 women, 916 men) in …
Oral Glucose-Lowering Agents vs Insulin for Gestational Diabetes: A Randomized Clinical Trial.
Rademaker D, de Wit L, Duijnhoven RG, Voormolen DN, Mol BW, Franx A, DeVries JH, Painter RC, van Rijn BB; SUGAR-DIP Study Group; Siegelaar SE, Akerboom BMC, Kiewiet-Kemper RM, Verwij-Didden MAL, Assouiki F, Kuppens SM, Oosterwerff MM, Stekkinger E, Diekman MJM, Vogelvang TE, Belle-van Meerkerk G, Galjaard S, Verdonk K, Lub A, Klooker TK, Krabbendam I, van Wijk JPH, Huisjes AJM, van Bemmel T, Nijman RGW, van den Beld AW, Hermes W, Johannsson-Vidarsdottir S, Vlug AG, Dullemond RC, Jansen HJ, Sueters M, de Koning EJP, van Laar JOEH, Wouters-van Poppel P, Evers IM, Sanson-van Praag ME, van den Akker ES, Brouwer CB, Hermsen BB, Scholten R, Meijer RI, van Leeuwen M, Wijbenga JAM, Wijnberger LDE, van Bon AC, van der Made FW, Eskes SA, Zandstra M, van Houtum WH, Braams-Lisman BAM, Daemen-Gubbels CRGM, Nijkamp JW, de Valk HW, Wouters MGAJ, IJzerman RG, Reiss I, van der Post JAM, Bosmans JE. Rademaker D, et al. JAMA. 2025 Feb 11;333(6):470-478. doi: 10.1001/jama.2024.23410. JAMA. 2025. PMID: 39761054 Clinical Trial.
IMPORTANCE: Metformin and glyburide monotherapy are used as alternatives to insulin in managing gestational diabetes. ...Glyburide was added to metformin, and then insulin substituted for glyburide, if needed, to achieve glucose targets. ...
IMPORTANCE: Metformin and glyburide monotherapy are used as alternatives to insulin in managing gestational diabetes. ...Gl …
Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT).
Kahn SE, Haffner SM, Viberti G, Herman WH, Lachin JM, Kravitz BG, Yu D, Paul G, Holman RR, Zinman B; Diabetes Outcome Progression Trial (ADOPT) Study Group. Kahn SE, et al. Diabetes Care. 2010 Jan;33(1):177-83. doi: 10.2337/dc09-1661. Epub 2009 Oct 6. Diabetes Care. 2010. PMID: 19808911 Free PMC article. Clinical Trial.
CRP reduction was greater in the rosiglitazone group by -47.6% relative to glyburide and by -30.5% relative to metformin at 48 months. Mean weight gain from baseline (at 48 months) was 5.6 kg with rosiglitazone, 1.8 kg with glyburide, and -2.8 kg with metf …
CRP reduction was greater in the rosiglitazone group by -47.6% relative to glyburide and by -30.5% relative to metformin at 48 …
Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus.
Silva JC, Fachin DR, Coral ML, Bertini AM. Silva JC, et al. J Perinat Med. 2012 Jan 10;40(3):225-8. doi: 10.1515/jpm-2011-0175. J Perinat Med. 2012. PMID: 22505499 Clinical Trial.
Patients were randomized to use metformin (n=104) or glyburide (n=96). The drugs were replaced by insulin when they reached the maximum dose without glycemic control. ...We found differences in weight (3193 g vs. 3387 g, P=0.01) and ponderal index (2.87 vs. 2.96, P= …
Patients were randomized to use metformin (n=104) or glyburide (n=96). The drugs were replaced by insulin when they reached th …
199 results